Intellia Therapeutics Q4 Earnings Call Highlights
Intellia Therapeutics (NASDAQ:NTLA) management used its fourth-quarter and full-year 2025 earnings call to highlight progress across its two lead in vivo CRISPR gene-editing programs—lonvo-z in hereditary angioedema (HAE) and Nex-z in transthyretin (TTR) amyloidosis—while providing updates on the regulatory status of its ATTR clinical trials and outlining commercial preparation for a potential HAE launch. Company [...]